#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Polycystic liver disease Dementia with Lewy bodies Primary myelofibrosis Small intestine adenocarcinoma Osteomyelitis Iron overload B-cell small lymphocytic lymphoma refractory VEXAS syndrome Prostate cancer Ewing's sarcoma Fibrosarcoma Neuroendocrine tumour Medulloblastoma recurrent Acquired C1 inhibitor deficiency Aspergillus infection More trials…

    Learn about Rare Diseases

    Leiomyosarcoma – Basic Information Chordoma – Diagnostics Extranodal marginal zone B-cell lymphoma (MALT type) Wiskott-Aldrich syndrome – Treatment Waldenstrom’s macroglobulinaemia refractory – Trials in Disease Myelodysplastic syndrome with excess blasts – Diagnostics Phenylketonuria – Life with Disease Paroxysmal nocturnal haemoglobinuria – Diagnostics Haemophilia – Life with Disease Rhabdoid tumour – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    MAPLIRPACEPT Linezolid Deferoxamine Cefalexin PHENTOLAMINE MESILATE Io102 Hydrochloride Deflazacort Dapagliflozin Propanediol Vinorelbine Tartrate Resmetirom POTASSIUM CLAVULANATE Hepatitis B Surface Antigen ZELENECTIDE PEVEDOTIN Potassium Chloride Nicotinamide POTASSIUM HYDROXIDE [18F]-Altanserin Doxorubicin Alitretinoin Vosilasarm More therapies…

    Learn about Your Condition

    Langerhans cell sarcoma Spinal osteoarthritis Thrombosis prophylaxis Hand dermatitis Low cardiac output syndrome Endometrial cancer Renal impairment Undifferentiated sarcoma Axial spondyloarthritis Patent ductus arteriosus Aicardi-Goutieres syndrome Psychotic disorder Partial lipodystrophy Post procedural oedema Epicondylitis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Breast cancer

  • Study on Alpelisib and Fulvestrant for Men and Postmenopausal Women with Advanced HR-positive, HER2-negative Breast Cancer with PIK3CA Mutation

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Alpelisib
    • Fulvestrant
    Belgium Bulgaria Czechia Denmark Finland France +10

  • Study of ribociclib combined with hormone therapy for patients with early-stage hormone receptor-positive, HER2-negative breast cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Anastrozole
    • Goserelin
    • Letrozole
    Austria Belgium France Germany Hungary Ireland +4

  • Study on Selpercatinib for Adults with Advanced or Metastatic Solid Tumors with RET Activation

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Colon cancer
    • Medullary thyroid cancer
    • Papillary thyroid cancer
    Investigated Drugs:
    • Selpercatinib
    France Italy Poland Spain

  • Study Comparing ARV-471 and Palbociclib with Letrozole and Palbociclib for Patients with Estrogen Receptor Positive, HER2-Negative Advanced Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • (3S)-3-[6-[4-[[1-[4-[(1R,2S)-6-Hydroxy-2-Phenyl-1,2,3,4-Tetrahydronaphthalen-1-Yl]Phenyl]Piperidin-4-Yl]Methyl]Piperazin-1-Yl]-3-Oxo-1H-Isoindol-2-Yl]Piperidine-2,6-Dione
    • Palbociclib
    Hungary Italy Slovakia Spain

  • Study on the Effects of Samuraciclib and Elacestrant for Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Samuraciclib
    • Elacestrant
    France Spain

  • Study of Fulvestrant and Samuraciclib for Patients with Advanced HR Positive, HER2-Negative Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    • Breast cancer
    Investigated Drugs:
    • Samuraciclib
    • Fulvestrant
    Hungary Spain
Previous Page
1 … 22 23 24 25 26 … 28
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!